Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07521007) titled 'A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis' on April 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Beijing Inno Medicine Co., Ltd.
Condition:
Atherosclerosis
Coronary Artery Disease
Intervention:
Drug: YN001/Placebo 40mg
Drug: YN001/Placebo 20mg
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 30, 2026
Target Sample Size: 456
Countries of Recruitment:...